23 May 2018
News and Views
Links and Services
The latest publication of the Alimentary Pharmacology & Therapeutics investigates immunogenicity and risk factors in patients with IBD severe infusion reactions to infliximab.
Infliximab elicits acute severe infusion reactions in about 5% of patients with inflammatory bowe
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors